Alto Neuroscience, Inc. (NYSE:ANRO) Short Interest Update

Alto Neuroscience, Inc. (NYSE:ANRO) was the target of a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 2,198,907 shares, a decline of 21.0% from the December 15th total of 2,781,726 shares. Based on an average trading volume of 490,970 shares, the days-to-cover ratio is currently 4.5 days. Currently, 7.1% of the shares of the company are sold short. Currently, 7.1% of the shares of the company are sold short. Based on an average trading volume of 490,970 shares, the days-to-cover ratio is currently 4.5 days.

Institutional Investors Weigh In On Alto Neuroscience

Several institutional investors have recently bought and sold shares of ANRO. Vanguard Personalized Indexing Management LLC increased its stake in Alto Neuroscience by 13.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after buying an additional 2,055 shares during the period. Peapod Lane Capital LLC boosted its holdings in shares of Alto Neuroscience by 1.1% in the third quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock valued at $1,136,000 after acquiring an additional 3,106 shares in the last quarter. Citizens Financial Group Inc. RI increased its stake in shares of Alto Neuroscience by 19.0% during the third quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock valued at $161,000 after acquiring an additional 6,394 shares during the period. AlphaCore Capital LLC raised its holdings in Alto Neuroscience by 100.0% during the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Bank of Montreal Can acquired a new stake in Alto Neuroscience in the second quarter worth approximately $25,000.

Alto Neuroscience Stock Performance

Shares of NYSE:ANRO traded up $0.19 during trading hours on Monday, hitting $17.21. The stock had a trading volume of 206,782 shares, compared to its average volume of 276,934. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42. The stock’s fifty day simple moving average is $15.75 and its 200 day simple moving average is $8.93. The firm has a market capitalization of $534.81 million, a price-to-earnings ratio of -7.52 and a beta of 2.78. Alto Neuroscience has a 1-year low of $1.60 and a 1-year high of $20.91.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.14. Sell-side analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wall Street Zen raised shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Chardan Capital lifted their price target on shares of Alto Neuroscience from $15.00 to $30.00 and gave the company a “buy” rating in a report on Monday, January 5th. HC Wainwright increased their price objective on shares of Alto Neuroscience from $10.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 24th. Jefferies Financial Group lifted their target price on Alto Neuroscience from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. Finally, Robert W. Baird upped their target price on Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $26.33.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.